

Diaceutics PLC - Issue of Share Options/PDMR Shareholdings
("Diaceutics" or the "Company")

Belfast and London, 25 October 2024 - Diaceutics PLC (AIM: DXRX), a leading technology and solutions provider to the pharma and biotech industry, announces the issue of 773,777 share options over ordinary shares of £0.002 each in the Company ("Share Options") to certain directors and a member of the Company's senior management team, pursuant to the Company's Employee Share Option Plan ("ESOP").

The Share Options were granted as follows:

Ryan Keeling (CEO) & Nick Roberts (CFO)

557,953 Share Options were granted to Ryan Keeling and 139,488 Share Options to Nick Roberts on 24 October 2024. These Share Options are granted over the balance of ordinary shares held in the Company's Employee Benefit Trust ("EBT") which have not been utilised to satisfy other employee share options at the time of exercise and are therefore non-dilutive to shareholders. The shares held by the EBT were originally gifted by Peter Keeling (Non-Executive Chairman and a co-founder) to the EBT pre-IPO with intention that the shares be used to incentivise directors and employees of the Company.

The Share Options will vest in full upon the satisfaction of certain shareholder value performance criteria over the performance period, being five years from the date of grant. The performance criteria are based upon growth in Total Shareholder Return ("TSR") during the performance period, the successful sole or joint listing of the Company on an alternative public stock exchange and other customary corporate events. The exercise price of the Share Options is £0.002 per share which equates to the nominal value of the ordinary shares.

The Share Options are granted over the balance of ordinary shares outstanding in the EBT at the point of exercise and may change depending on the number of outstanding ordinary shares in the EBT at that time.

Subsequent to the grant of the above Share Options, Ryan Keeling has 1,139,900 shares under option which represents 1.35% of the existing issued share capital of the Company and Nick Roberts has 467,110 shares under option which represents 0.55% of the existing issued share capital of the Company.

Sandra Blake, Chief People Officer (CPO)

76,336 Share Options were granted to Sandra Blake, a Person Discharging Managerial Responsibilities ('PDMR'), on 22 October 2024. The Share Options vest on a sliding scale up to 100%, during the performance period from the date of grant to 27 July 2027, subject to the satisfaction of certain performance criteria. The performance criteria are based upon the growth during the performance period in TSR, the revenue Compound Annual Growth Rate ("CAGR") and recurring revenue. The exercise price of the Share Options is £0.002 per share which equates to the nominal value of the ordinary shares. Subsequent to the grant, Sandra Blake has 76,336 shares under option which represents 0.09% of the existing issued share capital of the Company.

These awards are made in accordance with the Company's long term incentive plan as detailed in the Company's Annual Report.

Following this grant, the total number of share options outstanding in the Company is 5,168,180 representing approximately 6.10% of its current issued share capital of 84,726,935.

Enquiries:

Diaceutics PLC

Ryan Keeling, Chief Executive Officer
Nick Roberts, Chief Financial Officer

Tel: +44 (0)28 9040 6500
investorrelations@diaceutics.com

Canaccord Genuity Limited (Nomad & Broker)

Simon Bridges, Andrew Potts, Harry Rees

Tel: +44 (0)20 7523 8000

Alma Strategic Communications

Caroline Forde, Kinvara Verdon

Tel: +44(0)20 3405 0205
diaceutics@almastrategic.com

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network®.

The following additional information is disclosed in accordance with article 19(3) of the Market Abuse Regulation.

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1 Details of the person discharging managerial responsibilities/person closely associated

a.	Name	Ryan Keeling				
2 Reason for notification						
a.	Position/Status	Chief Executive Officer of Diaceutics plc				
b.	Initial notification/ Amendment	Initial				
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor						
a.	Name	Diaceutics plc				
b.	LEI	213800VEWQBB39ZB8J81				
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted						
a.	Description of the financial instrument, type of instrument Identification Code	Ordinary shares of 0.2 p each ISIN: GB00BJQTV64				
b.	N a t u r e o f t h e transaction	Grant of share options				
c.	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>Exercise price of 0.2p per share</td> <td>557,953</td> </tr> </tbody> </table>	Price(s)	Volume(s)	Exercise price of 0.2p per share	557,953
Price(s)	Volume(s)					
Exercise price of 0.2p per share	557,953					
e.	Date of the transaction	24 October 2024				
f.	Place of the transaction	Outside a trading venue				

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014		
1 Details of the person discharging managerial responsibilities/person closely associated		
a.	Name	Nick Roberts
2 Reason for notification		
a.	Position/Status	Chief Financial Officer of Diaceutics plc
b.	Initial notification/ Amendment	Initial
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a.	Name	Diaceutics plc
b.	LEI	213800VEWQBB39ZB8J81
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted		
a.	Description of the financial instrument, type of instrument Identification Code	Ordinary shares of 0.2 p each ISIN: GB00BJQTV64
b.	N a t u r e o f t h e transaction	Grant of share options
c.	Price(s) and volume(s)	

		<table border="1"> <tr> <td>Price(s)</td> <td>Volume(s)</td> </tr> <tr> <td>Exercise price of 0.2p per share</td> <td>139,488</td> </tr> </table>	Price(s)	Volume(s)	Exercise price of 0.2p per share	139,488
Price(s)	Volume(s)					
Exercise price of 0.2p per share	139,488					
e.	Date of the transaction	24 October 2024				
f.	Place of the transaction	Outside a trading venue				

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1 Details of the person discharging managerial responsibilities/person closely associated

a. Name Sandra Blake

2 Reason for notification

a. Position/Status Chief People Officer of Diaceutics plc

b. Initial notification/
Amendment Initial

3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a. Name Diaceutics plc

b. LEI 213800VEWQBB39ZB8J81

4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.	Description of the financial instrument, type of instrument Identification Code	Ordinary shares of 0.2 p each ISIN: GB00BJQTGV64				
b.	Nature of the transaction	Grant of share options				
c.	Price(s) and volume(s)	<table border="1"> <tr> <td>Price(s)</td> <td>Volume(s)</td> </tr> <tr> <td>Exercise price of 0.2p per share</td> <td>76,336</td> </tr> </table>	Price(s)	Volume(s)	Exercise price of 0.2p per share	76,336
Price(s)	Volume(s)					
Exercise price of 0.2p per share	76,336					
e.	Date of the transaction	22 October 2024				
f.	Place of the transaction	Outside a trading venue				

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHFZLLLZBLBFL